Maxygen, Inc. Announces Biomedical Advanced Research and Development Authority (BARDA) Decision Not to Award Contract for Development of MAXY-G34 for Acute Radiation Syndrome

Published: Nov 10, 2011

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Maxygen, Inc. (Nasdaq:MAXY) today announced that it has been advised by the Biomedical Advanced Research and Development Authority (BARDA) that Maxygen’s proposal for the development of its MAXY-G34 product candidate as a potential medical countermeasure for Acute Radiation Syndrome (ARS) will not be considered for a contract award.

Back to news